Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L [Thoracic Oncology]

Conclusion The study did not demonstrate noninferiority of gefitinib compared with erlotinib in terms of PFS in patients with lung adenocarcinoma according to the predefined criteria.

http://jco.ascopubs.org/cgi/content/short/34/27/3248?rss=1

Source: Journal of Clinical Oncology - September 12, 2016 Category: Cancer & Oncology Authors: Urata, Katakami, Morita, Kaji, Yoshioka, Seto, Satouchi, Iwamoto, Kanehara, Fujimoto, Ikeda, Murakami, Daga, Oguri, Goto, Imamura, Sugawara, Saka, Nogami, Negoro, Nakagawa, Nakanishi Tags: Chemotherapy Thoracic Oncology Source Type: research